---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-200068"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2022-07-22T23:59:59+00:00"
generated_at: "2026-06-24T09:34:52.655650+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cortexyme EVP of R&D Leslie Holsinger resigns effective July 31, 2022

## Summary
- Dr. Holsinger receives $339,000 cash severance (9 months' base salary) in a lump sum.
- Health care continuation benefits and 12-month extension of vested equity exercise period provided.
- Additional change-in-control severance and accelerated vesting available if a change in control occurs within 3 months post-departure.
- Company anticipates entering into a consulting agreement with Dr. Holsinger for transition through year-end.

## SEC filing metadata
- accession: 0001193125-22-200068
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2022-07-22T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312522200068/0001193125-22-200068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312522200068/d383988d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-200068
- JSON: https://secwatch.observer/filing/0001193125-22-200068.json
- Plain text: https://secwatch.observer/filing/0001193125-22-200068.txt

## Key facts
- Executive change
  Leslie Holsinger resigned as Executive Vice President of Research and Development at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President of Research and Development
  source text: On July 20, 2022, the Company entered into a transition agreement (the “Separation Agreement”) with Leslie Holsinger, Ph.D., relating to her resignation from her role as the Executive Vice President of Research and Development of the Company, effective as of July 31, 2022 (the “Departure Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522200068/0001193125-22-200068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.